Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3!
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
DEFINE_ME
www.esmoopen.com
December 7, 2024 at 7:52 AM
Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3!
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀
doi.org/10.1016/j.es...
doi.org/10.1016/j.es...
April 5, 2025 at 10:12 AM
Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀
doi.org/10.1016/j.es...
doi.org/10.1016/j.es...
Paolo Tarantino Started a New Role as Associate Editor for Breast Cancer at ESMO Open
@ptarantinomd.bsky.social @myesmo.bsky.social
oncodaily.com/career/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOOpen
@ptarantinomd.bsky.social @myesmo.bsky.social
oncodaily.com/career/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOOpen
Paolo Tarantino Started New Role as Associate Editor for Breast Cancer at ESMO Open - OncoDaily
Paolo Tarantino Started New Role as Associate Editor for Breast Cancer at ESMO Open / cancer, ESMO Open, OncoDaily, Oncology, Paolo Tarantino
oncodaily.com
August 5, 2025 at 1:40 PM
Paolo Tarantino Started a New Role as Associate Editor for Breast Cancer at ESMO Open
@ptarantinomd.bsky.social @myesmo.bsky.social
oncodaily.com/career/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOOpen
@ptarantinomd.bsky.social @myesmo.bsky.social
oncodaily.com/career/paolo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOOpen
The phase II FIGHT-202 trial’s final results reveal pemigatinib, a selective FGFR1-3 inhibitor, shows 37% ORR in patients with advanced/metastatic #CCA harboring #FGFR2 fusions/rearrangements (cohort A) 🌟
@myesmo.bsky.social #esmoopen
#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib
@myesmo.bsky.social #esmoopen
#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib
May 8, 2025 at 5:49 PM
The phase II FIGHT-202 trial’s final results reveal pemigatinib, a selective FGFR1-3 inhibitor, shows 37% ORR in patients with advanced/metastatic #CCA harboring #FGFR2 fusions/rearrangements (cohort A) 🌟
@myesmo.bsky.social #esmoopen
#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib
@myesmo.bsky.social #esmoopen
#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib
📝 We recently published the #ESMORTF position paper re: optimising well-being in the oncology workforce:
www.esmoopen.com/article/S205...
To supplement these recommendations, we have further detailed the qualitative data used in this piece - now out in #ESMOOpen 👇
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
To supplement these recommendations, we have further detailed the qualitative data used in this piece - now out in #ESMOOpen 👇
www.esmoopen.com/article/S205...
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series
The European Society for Medical Oncology (ESMO) Resilience Task Force (RTF) was established
to address burnout and well-being issues among oncology professionals. In this article,
we present findings...
www.esmoopen.com
March 14, 2025 at 8:03 PM
📝 We recently published the #ESMORTF position paper re: optimising well-being in the oncology workforce:
www.esmoopen.com/article/S205...
To supplement these recommendations, we have further detailed the qualitative data used in this piece - now out in #ESMOOpen 👇
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
To supplement these recommendations, we have further detailed the qualitative data used in this piece - now out in #ESMOOpen 👇
www.esmoopen.com/article/S205...
📢New publication alert!
Results from the EORTC-1560-GITCG (ILOC) phase II trial are now in #ESMOOpen.
The study assessed local ablative therapy + #immunotherapy in unresectable liver metastases from #colorectalcancer.
🔗Read more: www.eortc.org/bibliography/
#CancerResearch #EORTCgastrointestinal
Results from the EORTC-1560-GITCG (ILOC) phase II trial are now in #ESMOOpen.
The study assessed local ablative therapy + #immunotherapy in unresectable liver metastases from #colorectalcancer.
🔗Read more: www.eortc.org/bibliography/
#CancerResearch #EORTCgastrointestinal
July 29, 2025 at 10:22 AM
📢New publication alert!
Results from the EORTC-1560-GITCG (ILOC) phase II trial are now in #ESMOOpen.
The study assessed local ablative therapy + #immunotherapy in unresectable liver metastases from #colorectalcancer.
🔗Read more: www.eortc.org/bibliography/
#CancerResearch #EORTCgastrointestinal
Results from the EORTC-1560-GITCG (ILOC) phase II trial are now in #ESMOOpen.
The study assessed local ablative therapy + #immunotherapy in unresectable liver metastases from #colorectalcancer.
🔗Read more: www.eortc.org/bibliography/
#CancerResearch #EORTCgastrointestinal
For further details of the above-referenced paper, this is available #OpenAccess at #ESMOOpen.
#ESMO4Carers
📰 This is based on lessons learned from >3,700 colleagues from >100 countries: a synthesis of recommendations to manage psychosocial risks at work:
www.esmoopen.com/article/S205...
#ESMO4Carers
📰 This is based on lessons learned from >3,700 colleagues from >100 countries: a synthesis of recommendations to manage psychosocial risks at work:
www.esmoopen.com/article/S205...
November 16, 2024 at 7:31 PM
For further details of the above-referenced paper, this is available #OpenAccess at #ESMOOpen.
#ESMO4Carers
📰 This is based on lessons learned from >3,700 colleagues from >100 countries: a synthesis of recommendations to manage psychosocial risks at work:
www.esmoopen.com/article/S205...
#ESMO4Carers
📰 This is based on lessons learned from >3,700 colleagues from >100 countries: a synthesis of recommendations to manage psychosocial risks at work:
www.esmoopen.com/article/S205...
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Redirecting
doi.org
January 6, 2025 at 4:32 PM
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Millennials / Γιατί τόσοι νέοι εμφανίζουν καρκίνο
Millennials / Γιατί τόσοι νέοι εμφανίζουν καρκίνο
Οι millennials, δηλαδή όσοι γεννήθηκαν μεταξύ 1981 και 1995 είναι η πρώτη γενιά με μεγαλύτερο κίνδυνο εμφάνισης όγκων σε σχέση με τους γονείς τους, σύμφωνα με έρευνα που δημοσιεύεται στον επιστημονικό ιστότοπο esmoopen. Περίπου το 80% των καρκίνων δεν προκαλούνται από κληρονομικές μεταλλάξεις αλλά α
tvxs.gr
November 10, 2025 at 6:39 AM
Millennials / Γιατί τόσοι νέοι εμφανίζουν καρκίνο